SME biotech partner offering integrated genomic and epigenomic profiling for early cancer prediction

Aniling is an SME biotech company developing integrated genomic and epigenomic technologies for precision medicine, with a strong focus on early cancer prediction, molecular risk stratification and translational biomarker development.

We have developed GEUS, a proprietary technology that integrates genomic and epigenomic information into a single analytical workflow, designed to capture early molecular alterations associated with cancer risk and disease development. Our technology bridges the translational gap between complex multi-omics research and clinically deployable, cost-efficient diagnostic tools. It integrates seamlessly into existing NGS workflows and opens new avenues for multiplexed biomarker discovery and decentralised clinical validation.

Within the scope of the Cancer Mission, and particularly in relation to HORIZON-MISS-2026-02-CANCER-02 (Microbiome for early cancer prediction before the onset of disease), Aniling can contribute by:

• Integrating microbiome-derived data with host genomic and epigenomic features in a biologically meaningful way.

• Supporting the identification, prioritisation and interpretation of early molecular biomarkers relevant for cancer risk prediction.

• Contributing to the analytical comparison of microbiome-based approaches with other minimally invasive tests (e.g. liquid biopsy), from a multi-omics and biological interpretation perspective.

• Providing standardised and reproducible analytical workflows to support validation studies and future clinical translation.

Aniling has experience collaborating with academic and clinical partners in translational research settings. While we do not lead clinical cohorts, we are well positioned to act as a technology and analysis partner, complementing microbiome, clinical and data science expertise within a consortium.